THNR
Amplify Weight Loss Drug & Treatment ETFTHNR
THNR
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more funds holding
Funds holding: 2 [Q2] → 4 (+2) [Q3]
37% more capital invested
Capital invested by funds: $727K [Q2] → $994K (+$267K) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
2.63% less ownership
Funds ownership: 23.23% [Q2] → 20.6% (-2.63%) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for THNR.
Financial journalist opinion
Positive
ETF Trends
1 month ago
Disruptive Theme of the Week – Breakthroughs in Medicine
Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakthroughs and developments and explore a few ways to get actionable exposure to them with ETFs.
Positive
ETF Trends
1 month ago
Disruptive Theme of the Week: Happy Post-Election Themes
With the completion of a close presidential election, roughly half of us are likely disappointed regardless of the winner. To counter the post-election blues, I identified some “happy” ETF themes to consider for investment.
Positive
ETF Trends
1 month ago
Amplify ETFs Hits $10 Billion in Assets Amid New ETF Launches
As the ETF landscape continues to expand, more and more firms are crossing over significant AUM thresholds. That includes some now-veteran shops with strong, growing rosters, like Amplify ETFs.
Positive
Zacks Investment Research
3 months ago
Tap the Weight-Loss Drug Market With These ETFs
Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.
Neutral
ETF Trends
4 months ago
Disruptive Theme of the Week: Playing Defense
When markets correct, it is a good time to revisit which equity market sectors are “defensive” themes. Certain products and services are nondiscretionary in nature that we cannot live without.
Positive
Zacks Investment Research
5 months ago
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment
Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candidate.
Positive
Schwab Network
5 months ago
SILJ, HACK, THNR: Trends in Thematic Investing
Amplify Junior Silver Miners ETF (SILJ) is up 28% year-to-date. Christian Magoon discusses the outlook for cybersecurity stocks, as Amplify's Cybersecurity ETF (HACK) is up 8% year-to-date.
Positive
ETF Trends
5 months ago
Top Themes in the First Half of 2024: Crypto, Chips, Ships & Silver
After a torrid risk-on run in the first quarter of 2024, markets cooled off a bit but ended the half still positive with mid-double-digit returns. Technology themes such as cryptocurrency and artificial intelligence helped propel markets higher.
Negative
Investopedia
5 months ago
Why Investors Haven't Feasted on Two New Weight-Loss ETFs
Two new weight-loss exchange-traded funds (ETFs) launched in May have yet to whet investors' appetite, possibly due to their expensive fees and concentrated bets.
Neutral
ETF Trends
6 months ago
Finding Opportunity in Unloved Healthcare ETFs
Sometimes it feels like it's Nvidia's world and we all just live in it. Why bother with anything else?
Charts implemented using Lightweight Charts™